Cumberland Pharmaceuticals Advances Duchenne Muscular Dystrophy Treatment with FDA's Fast Track Designation Cumberland Pharmaceuticals has received FDA Fast Track Designation for its oral therapy targeting heart disease in Duchenne Muscular Dystrophy, speeding up development for urgent medical need.

Cumberland Pharmaceuticals Advances Duchenne Muscular Dystrophy Treatment with FDA's Fast Track Designation #USA #Nashville #ifetroban #DMD #Cumberland_Pharma

Cumberland Pharmaceuticals Achieves Impressive 38% Revenue Growth in Q1 2025 Cumberland Pharmaceuticals Inc. reported a remarkable 38% revenue increase in Q1 2025, driven by strong performance and expansion plans.

Cumberland Pharmaceuticals Achieves Impressive 38% Revenue Growth in Q1 2025 #United_States #Nashville #revenue_growth #FDA_Approved #Cumberland_Pharma